Loading
A phase 3 trial of an investigational treatment in prostate cancer, run by Norroy Bioscience Co., LTD, now recruiting.
This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer. is a phase 3 interventional study registered as NCT07649122 by Norroy Bioscience Co., LTD, with 232 participants planned, started 2026-08-31 and due to reach its primary completion in 2028-06-30.
Shares Norroy Bioscience, PET (positron emission tomography), PET/CT, Prostate cancer and the tag pipeline.
Shares Norroy Bioscience, Prostate cancer and the tag pipeline.
Shares PET (positron emission tomography), PET/CT, Prostate cancer and the tag pipeline.
Shares PET (positron emission tomography), PET/CT, Prostate cancer and the tag pipeline.
Shares PET (positron emission tomography), Prostate cancer and the tag pipeline.
Shares PET (positron emission tomography), Prostate cancer and the tag pipeline.
Shares PET (positron emission tomography), PET/CT and the tag pipeline.
Shares PET (positron emission tomography), PET/CT and the tag pipeline.